Author: "Lucidi, V" / Database: OAIster - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Lucidi, V"' showing total 31 results

Start Over Author "Lucidi, V" Database OAIster

31 results on '"Lucidi, V"'

1. Histopathological growth patterns of neuroendocrine tumor liver metastases

Author: Meyer, Y., Bohlok, A., Olthof, P., Donckier, V., Doukas, M., Lucidi, V., Vermeulen, P., Grünhagen, D., Verhoef, C., Meyer, Y., Bohlok, A., Olthof, P., Donckier, V., Doukas, M., Lucidi, V., Vermeulen, P., Grünhagen, D., and Verhoef, C.
Abstract: Histopathological growth patterns (HGPs) of liver metastases represent a potential biomarker for prognosis after resection. They have never been studied in neuroendocrine tumor liver metastases (NETLM). This study evaluated if distinct HGPs can be observed in resected NETLM and if they have prognostic value. Sixty-three patients who underwent resection of NETLM between 01–01-2001 and 31–12-2021 were retrospectively included. HGPs were scored on Haematoxylin&Eosin slides using light microscopy, distinguishing desmoplastic- (dHGP), pushing- (pHGP) and replacement HGP (rHGP). Average HGP scores were calculated per patient. Each patient was classified according to predominant HGP. Overall and Disease-Free Survival (OS and DFS) were evaluated through Kaplan–Meier analysis and Cox regression. Eighteen patients had predominant dHGP (29%), 33 had predominant pHGP (52%) and 11 had predominant rHGP (17%). One patient had mixed HGP (2%). Five-year OS was 76% (95%CI: 66–87%) for the overall cohort. Five-year OS was 92% (95%CI: 77–100%) for dHGP, was 73% (95%CI: 59–91%) for pHGP, 50% (95%CI: 25–100%) for rHGP. Five-year DFS was 39% (95%CI: 19–83%) for dHGP, 44% (95%CI: 27–71%) for rHGP and 50% (95%CI: 23–100%) for pHGP. There was no significant association between HGP and OS or DFS in multivariable analysis. Distinct HGPs could be identified in NETLM. In patients who underwent resection of NETLM, no association was found between HGPs and postoperative survival. Half of the patients with NETLM have a predominant pushing growth pattern, which is a rare growth pattern in liver metastases from breast and colorectal cancer.
Published: 2023

2. Dragon 1 Protocol Manuscript : Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

Author: Korenblik, R., Olij, B., Aldrighetti, L. A., Abu Hilal, M., Ahle, Margareta, Arslan, B., van Baardewijk, L. J., Baclija, I, Bent, C., Bertrand, C. L., Björnsson, Bergthor, de Boer, M. T., de Boer, S. W., Bokkers, R. P. H., Rinkes, I. H. M. Borel, Breitenstein, S., Bruijnen, R. C. G., Bruners, P., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K. Y., Chang, D. H., Choi, J., Codina Font, J., Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Dili, A., Erdmann, J. I, Fisher, O., Fondevila, C., Fretland, A., Garcia Borobia, F., Gelabert, A., Gerard, L., Giuliante, F., Gobardhan, P. D., Gomez, F., Grunberger, T., Grunhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K. G., Lopez Ben, S., Lucidi, V, MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Sampere Moragues, J., Sandström, Per A, Sarria, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L. J., Sparrelid, E., Spuntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I, Tasse, J. C., Udupa, V, Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A. J., Binkert, C. A., Bemelmans, M. H. A., van der Leij, C., Schadde, E., van Dam, R. M., Korenblik, R., Olij, B., Aldrighetti, L. A., Abu Hilal, M., Ahle, Margareta, Arslan, B., van Baardewijk, L. J., Baclija, I, Bent, C., Bertrand, C. L., Björnsson, Bergthor, de Boer, M. T., de Boer, S. W., Bokkers, R. P. H., Rinkes, I. H. M. Borel, Breitenstein, S., Bruijnen, R. C. G., Bruners, P., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K. Y., Chang, D. H., Choi, J., Codina Font, J., Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Dili, A., Erdmann, J. I, Fisher, O., Fondevila, C., Fretland, A., Garcia Borobia, F., Gelabert, A., Gerard, L., Giuliante, F., Gobardhan, P. D., Gomez, F., Grunberger, T., Grunhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K. G., Lopez Ben, S., Lucidi, V, MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Sampere Moragues, J., Sandström, Per A, Sarria, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L. J., Sparrelid, E., Spuntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I, Tasse, J. C., Udupa, V, Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A. J., Binkert, C. A., Bemelmans, M. H. A., van der Leij, C., Schadde, E., and van Dam, R. M.
Abstract: Study Purpose The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases. Methods The DRAGON 1 trial is a worldwide multicenter prospective single arm trial. The primary endpoint is a composite of the safety of PVE/HVE, 90-day mortality, and one year accrual monitoring of each participating center. Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. Liver volumes will be measured at week 1 and if applicable at week 3 and 6 after PVE/HVE and follow-up visits will be held at 1, 3, 6, and 12 months after the resection. Results Not applicable. Conclusion DRAGON 1 is a prospective trial to assess the safety and feasibility of PVE/HVE. Participating study centers will be trained, and procedures standardized using Work Instructions (WI) to prepare for the DRAGON 2 randomized controlled trial. Outcomes should reveal the accrual potential of centers, safety profile of combined PVE/HVE and the effect of FLR-hypertrophy induction by PVE/HVE in patients with CRLM and a small FLR., Funding Agencies|Dutch Cancer Society (KWF); Abbott Laboratories; Maastricht University; Maastricht University Medical Center; NIHR; Guerbet
Published: 2022
Full Text: View/download PDF

3. Dragon 1 Protocol Manuscript : Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

Author: Korenblik, R., Olij, B., Aldrighetti, L. A., Abu Hilal, M., Ahle, Margareta, Arslan, B., van Baardewijk, L. J., Baclija, I, Bent, C., Bertrand, C. L., Björnsson, Bergthor, de Boer, M. T., de Boer, S. W., Bokkers, R. P. H., Rinkes, I. H. M. Borel, Breitenstein, S., Bruijnen, R. C. G., Bruners, P., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K. Y., Chang, D. H., Choi, J., Codina Font, J., Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Dili, A., Erdmann, J. I, Fisher, O., Fondevila, C., Fretland, A., Garcia Borobia, F., Gelabert, A., Gerard, L., Giuliante, F., Gobardhan, P. D., Gomez, F., Grunberger, T., Grunhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K. G., Lopez Ben, S., Lucidi, V, MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Sampere Moragues, J., Sandström, Per A, Sarria, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L. J., Sparrelid, E., Spuntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I, Tasse, J. C., Udupa, V, Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A. J., Binkert, C. A., Bemelmans, M. H. A., van der Leij, C., Schadde, E., van Dam, R. M., Korenblik, R., Olij, B., Aldrighetti, L. A., Abu Hilal, M., Ahle, Margareta, Arslan, B., van Baardewijk, L. J., Baclija, I, Bent, C., Bertrand, C. L., Björnsson, Bergthor, de Boer, M. T., de Boer, S. W., Bokkers, R. P. H., Rinkes, I. H. M. Borel, Breitenstein, S., Bruijnen, R. C. G., Bruners, P., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K. Y., Chang, D. H., Choi, J., Codina Font, J., Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Dili, A., Erdmann, J. I, Fisher, O., Fondevila, C., Fretland, A., Garcia Borobia, F., Gelabert, A., Gerard, L., Giuliante, F., Gobardhan, P. D., Gomez, F., Grunberger, T., Grunhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K. G., Lopez Ben, S., Lucidi, V, MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Sampere Moragues, J., Sandström, Per A, Sarria, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L. J., Sparrelid, E., Spuntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I, Tasse, J. C., Udupa, V, Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A. J., Binkert, C. A., Bemelmans, M. H. A., van der Leij, C., Schadde, E., and van Dam, R. M.
Abstract: Study Purpose The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases. Methods The DRAGON 1 trial is a worldwide multicenter prospective single arm trial. The primary endpoint is a composite of the safety of PVE/HVE, 90-day mortality, and one year accrual monitoring of each participating center. Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. Liver volumes will be measured at week 1 and if applicable at week 3 and 6 after PVE/HVE and follow-up visits will be held at 1, 3, 6, and 12 months after the resection. Results Not applicable. Conclusion DRAGON 1 is a prospective trial to assess the safety and feasibility of PVE/HVE. Participating study centers will be trained, and procedures standardized using Work Instructions (WI) to prepare for the DRAGON 2 randomized controlled trial. Outcomes should reveal the accrual potential of centers, safety profile of combined PVE/HVE and the effect of FLR-hypertrophy induction by PVE/HVE in patients with CRLM and a small FLR., Funding Agencies|Dutch Cancer Society (KWF); Abbott Laboratories; Maastricht University; Maastricht University Medical Center; NIHR; Guerbet
Published: 2022
Full Text: View/download PDF

4. Long-term outcome of liver transplantation for unresectable liver metastases from Neuroendocrine neoplasms: a Belgian retrospective multi-centre study

Author: UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service de chirurgie et transplantation abdominale, UCL - (SLuc) Service de gastro-entérologie, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, Bonaccorsi Riani, Eliano, Pulido Cloquell, Ignacio, Detry, O, Meurisse, N, Ysebaert, D, Pirenne, J, Verslype, C, Berrevoet, F, Vanlander, A, Lucidi, V, Coubeau, Laurent, Dahlqvist, Géraldine, Ciccarelli, Olga, Borbath, Ivan, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service de chirurgie et transplantation abdominale, UCL - (SLuc) Service de gastro-entérologie, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, Bonaccorsi Riani, Eliano, Pulido Cloquell, Ignacio, Detry, O, Meurisse, N, Ysebaert, D, Pirenne, J, Verslype, C, Berrevoet, F, Vanlander, A, Lucidi, V, Coubeau, Laurent, Dahlqvist, Géraldine, Ciccarelli, Olga, and Borbath, Ivan
Published: 2022

5. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy.

Author: UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de chirurgie, UCL - (MGD) Service de radiologie - résonance magnétique, Korenblik, R, Olij, B, Aldrighetti, L A, Hilal, M Abu, Ahle, M, Arslan, B, van Baardewijk, L J, Baclija, I, Bent, C, Claude, Bertrand, Björnsson, B, de Boer, M T, de Boer, S W, Bokkers, R P H, Rinkes, I H M Borel, Breitenstein, S, Bruijnen, R C G, Bruners, P, Büchler, M W, Camacho, J C, Cappelli, A, Carling, U, Chan, B K Y, Chang, D H, Choi, J, Font, J Codina, Crawford, M, Croagh, D, Cugat, E, Davis, R, De Boo, D W, De Cobelli, F, De Wispelaere, Jean-François, van Delden, O M, Delle, M, Detry, O, Díaz-Nieto, R, Dili, Alexandra, Erdmann, J I, Fisher, O, Fondevila, C, Fretland, Å, Borobia, F Garcia, Gelabert, A, Gérard, L, Giuliante, F, Gobardhan, P D, Gómez, F, Grünberger, T, Grünhagen, D J, Guitart, J, Hagendoorn, J, Heil, J, Heise, D, Herrero, E, Hess, G F, Hoffmann, M H, Iezzi, R, Imani, F, Nguyen, J, Jovine, E, Kalff, J C, Kazemier, G, Kingham, T P, Kleeff, J, Kollmar, O, Leclercq, W K G, Ben, S Lopez, Lucidi, V, MacDonald, A, Madoff, D C, Manekeller, S, Martel, G, Mehrabi, A, Mehrzad, H, Meijerink, M R, Menon, K, Metrakos, P, Meyer, C, Moelker, A, Modi, S, Montanari, N, Navines, J, Neumann, U P, Peddu, P, Primrose, J N, Qu, X, Raptis, D, Ratti, F, Ridouani, F, Rogan, C, Ronellenfitsch, U, Ryan, S, Sallemi, C, Moragues, J Sampere, Sandström, P, Sarriá, L, Schnitzbauer, A, Serenari, M, Serrablo, A, Smits, M L J, Sparrelid, E, Spüntrup, E, Stavrou, G A, Sutcliffe, R P, Tancredi, I, Tasse, J C, Udupa, V, Valenti, D, Fundora, Y, Vogl, T J, Wang, X, White, S A, Wohlgemuth, W A, Yu, D, Zijlstra, I A J, Binkert, C A, Bemelmans, M H A, van der Leij, C, Schadde, E, van Dam, R M, UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de chirurgie, UCL - (MGD) Service de radiologie - résonance magnétique, Korenblik, R, Olij, B, Aldrighetti, L A, Hilal, M Abu, Ahle, M, Arslan, B, van Baardewijk, L J, Baclija, I, Bent, C, Claude, Bertrand, Björnsson, B, de Boer, M T, de Boer, S W, Bokkers, R P H, Rinkes, I H M Borel, Breitenstein, S, Bruijnen, R C G, Bruners, P, Büchler, M W, Camacho, J C, Cappelli, A, Carling, U, Chan, B K Y, Chang, D H, Choi, J, Font, J Codina, Crawford, M, Croagh, D, Cugat, E, Davis, R, De Boo, D W, De Cobelli, F, De Wispelaere, Jean-François, van Delden, O M, Delle, M, Detry, O, Díaz-Nieto, R, Dili, Alexandra, Erdmann, J I, Fisher, O, Fondevila, C, Fretland, Å, Borobia, F Garcia, Gelabert, A, Gérard, L, Giuliante, F, Gobardhan, P D, Gómez, F, Grünberger, T, Grünhagen, D J, Guitart, J, Hagendoorn, J, Heil, J, Heise, D, Herrero, E, Hess, G F, Hoffmann, M H, Iezzi, R, Imani, F, Nguyen, J, Jovine, E, Kalff, J C, Kazemier, G, Kingham, T P, Kleeff, J, Kollmar, O, Leclercq, W K G, Ben, S Lopez, Lucidi, V, MacDonald, A, Madoff, D C, Manekeller, S, Martel, G, Mehrabi, A, Mehrzad, H, Meijerink, M R, Menon, K, Metrakos, P, Meyer, C, Moelker, A, Modi, S, Montanari, N, Navines, J, Neumann, U P, Peddu, P, Primrose, J N, Qu, X, Raptis, D, Ratti, F, Ridouani, F, Rogan, C, Ronellenfitsch, U, Ryan, S, Sallemi, C, Moragues, J Sampere, Sandström, P, Sarriá, L, Schnitzbauer, A, Serenari, M, Serrablo, A, Smits, M L J, Sparrelid, E, Spüntrup, E, Stavrou, G A, Sutcliffe, R P, Tancredi, I, Tasse, J C, Udupa, V, Valenti, D, Fundora, Y, Vogl, T J, Wang, X, White, S A, Wohlgemuth, W A, Yu, D, Zijlstra, I A J, Binkert, C A, Bemelmans, M H A, van der Leij, C, Schadde, E, and van Dam, R M
Abstract: The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases. The DRAGON 1 trial is a worldwide multicenter prospective single arm trial. The primary endpoint is a composite of the safety of PVE/HVE, 90-day mortality, and one year accrual monitoring of each participating center. Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. Liver volumes will be measured at week 1 and if applicable at week 3 and 6 after PVE/HVE and follow-up visits will be held at 1, 3, 6, and 12 months after the resection. Not applicable. DRAGON 1 is a prospective trial to assess the safety and feasibility of PVE/HVE. Participating study centers will be trained, and procedures standardized using Work Instructions (WI) to prepare for the DRAGON 2 randomized controlled trial. Outcomes should reveal the accrual potential of centers, safety profile of combined PVE/HVE and the effect of FLR-hypertrophy induction by PVE/HVE in patients with CRLM and a small FLR. Clinicaltrials.gov: NCT04272931 (February 17, 2020). Toestingonline.nl: NL71535.068.19 (September 20, 2019).
Published: 2022

6. Dragon 1 Protocol Manuscript : Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

Author: Korenblik, R., Olij, B., Aldrighetti, L. A., Abu Hilal, M., Ahle, Margareta, Arslan, B., van Baardewijk, L. J., Baclija, I, Bent, C., Bertrand, C. L., Björnsson, Bergthor, de Boer, M. T., de Boer, S. W., Bokkers, R. P. H., Rinkes, I. H. M. Borel, Breitenstein, S., Bruijnen, R. C. G., Bruners, P., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K. Y., Chang, D. H., Choi, J., Codina Font, J., Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Dili, A., Erdmann, J. I, Fisher, O., Fondevila, C., Fretland, A., Garcia Borobia, F., Gelabert, A., Gerard, L., Giuliante, F., Gobardhan, P. D., Gomez, F., Grunberger, T., Grunhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K. G., Lopez Ben, S., Lucidi, V, MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Sampere Moragues, J., Sandström, Per A, Sarria, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L. J., Sparrelid, E., Spuntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I, Tasse, J. C., Udupa, V, Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A. J., Binkert, C. A., Bemelmans, M. H. A., van der Leij, C., Schadde, E., van Dam, R. M., Korenblik, R., Olij, B., Aldrighetti, L. A., Abu Hilal, M., Ahle, Margareta, Arslan, B., van Baardewijk, L. J., Baclija, I, Bent, C., Bertrand, C. L., Björnsson, Bergthor, de Boer, M. T., de Boer, S. W., Bokkers, R. P. H., Rinkes, I. H. M. Borel, Breitenstein, S., Bruijnen, R. C. G., Bruners, P., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K. Y., Chang, D. H., Choi, J., Codina Font, J., Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Dili, A., Erdmann, J. I, Fisher, O., Fondevila, C., Fretland, A., Garcia Borobia, F., Gelabert, A., Gerard, L., Giuliante, F., Gobardhan, P. D., Gomez, F., Grunberger, T., Grunhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K. G., Lopez Ben, S., Lucidi, V, MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Sampere Moragues, J., Sandström, Per A, Sarria, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L. J., Sparrelid, E., Spuntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I, Tasse, J. C., Udupa, V, Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A. J., Binkert, C. A., Bemelmans, M. H. A., van der Leij, C., Schadde, E., and van Dam, R. M.
Abstract: Study Purpose The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases. Methods The DRAGON 1 trial is a worldwide multicenter prospective single arm trial. The primary endpoint is a composite of the safety of PVE/HVE, 90-day mortality, and one year accrual monitoring of each participating center. Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. Liver volumes will be measured at week 1 and if applicable at week 3 and 6 after PVE/HVE and follow-up visits will be held at 1, 3, 6, and 12 months after the resection. Results Not applicable. Conclusion DRAGON 1 is a prospective trial to assess the safety and feasibility of PVE/HVE. Participating study centers will be trained, and procedures standardized using Work Instructions (WI) to prepare for the DRAGON 2 randomized controlled trial. Outcomes should reveal the accrual potential of centers, safety profile of combined PVE/HVE and the effect of FLR-hypertrophy induction by PVE/HVE in patients with CRLM and a small FLR., Funding Agencies|Dutch Cancer Society (KWF); Abbott Laboratories; Maastricht University; Maastricht University Medical Center; NIHR; Guerbet
Published: 2022
Full Text: View/download PDF

7. Dragon 1 Protocol Manuscript : Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

Author: Korenblik, R., Olij, B., Aldrighetti, L. A., Abu Hilal, M., Ahle, Margareta, Arslan, B., van Baardewijk, L. J., Baclija, I, Bent, C., Bertrand, C. L., Björnsson, Bergthor, de Boer, M. T., de Boer, S. W., Bokkers, R. P. H., Rinkes, I. H. M. Borel, Breitenstein, S., Bruijnen, R. C. G., Bruners, P., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K. Y., Chang, D. H., Choi, J., Codina Font, J., Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Dili, A., Erdmann, J. I, Fisher, O., Fondevila, C., Fretland, A., Garcia Borobia, F., Gelabert, A., Gerard, L., Giuliante, F., Gobardhan, P. D., Gomez, F., Grunberger, T., Grunhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K. G., Lopez Ben, S., Lucidi, V, MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Sampere Moragues, J., Sandström, Per A, Sarria, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L. J., Sparrelid, E., Spuntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I, Tasse, J. C., Udupa, V, Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A. J., Binkert, C. A., Bemelmans, M. H. A., van der Leij, C., Schadde, E., van Dam, R. M., Korenblik, R., Olij, B., Aldrighetti, L. A., Abu Hilal, M., Ahle, Margareta, Arslan, B., van Baardewijk, L. J., Baclija, I, Bent, C., Bertrand, C. L., Björnsson, Bergthor, de Boer, M. T., de Boer, S. W., Bokkers, R. P. H., Rinkes, I. H. M. Borel, Breitenstein, S., Bruijnen, R. C. G., Bruners, P., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K. Y., Chang, D. H., Choi, J., Codina Font, J., Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Dili, A., Erdmann, J. I, Fisher, O., Fondevila, C., Fretland, A., Garcia Borobia, F., Gelabert, A., Gerard, L., Giuliante, F., Gobardhan, P. D., Gomez, F., Grunberger, T., Grunhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K. G., Lopez Ben, S., Lucidi, V, MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Sampere Moragues, J., Sandström, Per A, Sarria, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L. J., Sparrelid, E., Spuntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I, Tasse, J. C., Udupa, V, Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A. J., Binkert, C. A., Bemelmans, M. H. A., van der Leij, C., Schadde, E., and van Dam, R. M.
Abstract: Study Purpose The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases. Methods The DRAGON 1 trial is a worldwide multicenter prospective single arm trial. The primary endpoint is a composite of the safety of PVE/HVE, 90-day mortality, and one year accrual monitoring of each participating center. Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. Liver volumes will be measured at week 1 and if applicable at week 3 and 6 after PVE/HVE and follow-up visits will be held at 1, 3, 6, and 12 months after the resection. Results Not applicable. Conclusion DRAGON 1 is a prospective trial to assess the safety and feasibility of PVE/HVE. Participating study centers will be trained, and procedures standardized using Work Instructions (WI) to prepare for the DRAGON 2 randomized controlled trial. Outcomes should reveal the accrual potential of centers, safety profile of combined PVE/HVE and the effect of FLR-hypertrophy induction by PVE/HVE in patients with CRLM and a small FLR., Funding Agencies|Dutch Cancer Society (KWF); Abbott Laboratories; Maastricht University; Maastricht University Medical Center; NIHR; Guerbet
Published: 2022
Full Text: View/download PDF

8. Dragon 1 Protocol Manuscript : Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

Author: Korenblik, R., Olij, B., Aldrighetti, L. A., Abu Hilal, M., Ahle, Margareta, Arslan, B., van Baardewijk, L. J., Baclija, I, Bent, C., Bertrand, C. L., Björnsson, Bergthor, de Boer, M. T., de Boer, S. W., Bokkers, R. P. H., Rinkes, I. H. M. Borel, Breitenstein, S., Bruijnen, R. C. G., Bruners, P., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K. Y., Chang, D. H., Choi, J., Codina Font, J., Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Dili, A., Erdmann, J. I, Fisher, O., Fondevila, C., Fretland, A., Garcia Borobia, F., Gelabert, A., Gerard, L., Giuliante, F., Gobardhan, P. D., Gomez, F., Grunberger, T., Grunhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K. G., Lopez Ben, S., Lucidi, V, MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Sampere Moragues, J., Sandström, Per A, Sarria, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L. J., Sparrelid, E., Spuntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I, Tasse, J. C., Udupa, V, Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A. J., Binkert, C. A., Bemelmans, M. H. A., van der Leij, C., Schadde, E., van Dam, R. M., Korenblik, R., Olij, B., Aldrighetti, L. A., Abu Hilal, M., Ahle, Margareta, Arslan, B., van Baardewijk, L. J., Baclija, I, Bent, C., Bertrand, C. L., Björnsson, Bergthor, de Boer, M. T., de Boer, S. W., Bokkers, R. P. H., Rinkes, I. H. M. Borel, Breitenstein, S., Bruijnen, R. C. G., Bruners, P., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K. Y., Chang, D. H., Choi, J., Codina Font, J., Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Dili, A., Erdmann, J. I, Fisher, O., Fondevila, C., Fretland, A., Garcia Borobia, F., Gelabert, A., Gerard, L., Giuliante, F., Gobardhan, P. D., Gomez, F., Grunberger, T., Grunhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K. G., Lopez Ben, S., Lucidi, V, MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Sampere Moragues, J., Sandström, Per A, Sarria, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L. J., Sparrelid, E., Spuntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I, Tasse, J. C., Udupa, V, Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A. J., Binkert, C. A., Bemelmans, M. H. A., van der Leij, C., Schadde, E., and van Dam, R. M.
Abstract: Study Purpose The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases. Methods The DRAGON 1 trial is a worldwide multicenter prospective single arm trial. The primary endpoint is a composite of the safety of PVE/HVE, 90-day mortality, and one year accrual monitoring of each participating center. Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. Liver volumes will be measured at week 1 and if applicable at week 3 and 6 after PVE/HVE and follow-up visits will be held at 1, 3, 6, and 12 months after the resection. Results Not applicable. Conclusion DRAGON 1 is a prospective trial to assess the safety and feasibility of PVE/HVE. Participating study centers will be trained, and procedures standardized using Work Instructions (WI) to prepare for the DRAGON 2 randomized controlled trial. Outcomes should reveal the accrual potential of centers, safety profile of combined PVE/HVE and the effect of FLR-hypertrophy induction by PVE/HVE in patients with CRLM and a small FLR., Funding Agencies|Dutch Cancer Society (KWF); Abbott Laboratories; Maastricht University; Maastricht University Medical Center; NIHR; Guerbet
Published: 2022
Full Text: View/download PDF

9. Dragon 1 Protocol Manuscript:Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

Author: Korenblik, R., Olij, B., Aldrighetti, L. A., Hilal, M. Abu, Ahle, M., Arslan, B., van Baardewijk, L. J., Baclija, I., Bent, C., Bertrand, C. L., Björnsson, B., de Boer, M. T., de Boer, S. W., Bokkers, R. P.H., Rinkes, I. H.M.Borel, Breitenstein, S., Bruijnen, R. C.G., Bruners, P., Büchler, M. W., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K.Y., Chang, D. H., choi, J., Font, J. Codina, Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Díaz-Nieto, R., Dili, A., Erdmann, J. I., Fisher, O., Fondevila, C., Fretland, Borobia, F. Garcia, Gelabert, A., Gérard, L., Giuliante, F., Gobardhan, P. D., Gómez, F., Grünberger, T., Grünhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K.G., Ben, S. Lopez, Lucidi, V., MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Moragues, J. Sampere, Sandström, P., Sarriá, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L.J., Sparrelid, E., Spüntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I., Tasse, J. C., Udupa, V., Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A.J., Binkert, C. A., Bemelmans, M. H.A., van der Leij, C., Schadde, E., van Dam, R. M., Korenblik, R., Olij, B., Aldrighetti, L. A., Hilal, M. Abu, Ahle, M., Arslan, B., van Baardewijk, L. J., Baclija, I., Bent, C., Bertrand, C. L., Björnsson, B., de Boer, M. T., de Boer, S. W., Bokkers, R. P.H., Rinkes, I. H.M.Borel, Breitenstein, S., Bruijnen, R. C.G., Bruners, P., Büchler, M. W., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K.Y., Chang, D. H., choi, J., Font, J. Codina, Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Díaz-Nieto, R., Dili, A., Erdmann, J. I., Fisher, O., Fondevila, C., Fretland, Borobia, F. Garcia, Gelabert, A., Gérard, L., Giuliante, F., Gobardhan, P. D., Gómez, F., Grünberger, T., Grünhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K.G., Ben, S. Lopez, Lucidi, V., MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Moragues, J. Sampere, Sandström, P., Sarriá, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L.J., Sparrelid, E., Spüntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I., Tasse, J. C., Udupa, V., Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A.J., Binkert, C. A., Bemelmans, M. H.A., van der Leij, C., Schadde, E., and van Dam, R. M.
Abstract: Study Purpose: The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases. Methods: The DRAGON 1 trial is a worldwide multicenter prospective single arm trial. The primary endpoint is a composite of the safety of PVE/HVE, 90-day mortality, and one year accrual monitoring of each participating center. Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. Liver volumes will be measured at week 1 and if applicable at week 3 and 6 after PVE/HVE and follow-up visits will be held at 1, 3, 6, and 12 months after the resection. Results: Not applicable. Conclusion: DRAGON 1 is a prospective trial to assess the safety and feasibility of PVE/HVE. Participating study centers will be trained, and procedures standardized using Work Instructions (WI) to prepare for the DRAGON 2 randomized controlled trial. Outcomes should reveal the accrual potential of centers, safety profile of combined PVE/HVE and the effect of FLR-hypertrophy induction by PVE/HVE in patients with CRLM and a small FLR. Trial Registration: Clinicaltrials.gov: NCT04272931 (February 17, 2020). Toestingonline.nl: NL71535.068.19 (September 20, 2019).
Published: 2022

10. A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation

Author: Schlegel, A, van Reeven, M, Croome, K, Parente, A, Dolcet, A, Widmer, J, Meurisse, N, De Carlis, R, Hessheimer, A, Jochmans, I, Mueller, M, van Leeuwen, O, Nair, A, Tomiyama, K, Sherif, A, Elsharif, M, Kron, P, van der Helm, D, Borja-Cacho, D, Bohorquez, H, Germanova, D, Dondossola, D, Olivieri, T, Camagni, S, Gorgen, A, Patrono, D, Cescon, M, Croome, S, Panconesi, R, Flores Carvalho, M, Ravaioli, M, Caicedo, J, Loss, G, Lucidi, V, Sapisochin, G, Romagnoli, R, Jassem, W, Colledan, M, De Carlis, L, Rossi, G, Di Benedetto, F, Miller, C, van Hoek, B, Attia, M, Lodge, P, Hernandez-Alejandro, R, Detry, O, Quintini, C, Oniscu, G, Fondevila, C, Malagó, M, Pirenne, J, Ijzermans, J, Porte, R, Dutkowski, P, Taner, C, Heaton, N, Clavien, P, Polak, W, Muiesan, P, Schlegel, Andrea, van Reeven, Marjolein, Croome, Kristopher, Parente, Alessandro, Dolcet, Annalisa, Widmer, Jeannette, Meurisse, Nicolas, De Carlis, Riccardo, Hessheimer, Amelia, Jochmans, Ina, Mueller, Matteo, van Leeuwen, Otto B, Nair, Amit, Tomiyama, Koji, Sherif, Ahmed, Elsharif, Mohamed, Kron, Philipp, van der Helm, Danny, Borja-Cacho, Daniel, Bohorquez, Humberto, Germanova, Desislava, Dondossola, Daniele, Olivieri, Tiziana, Camagni, Stefania, Gorgen, Andre, Patrono, Damiano, Cescon, Matteo, Croome, Sarah, Panconesi, Rebecca, Flores Carvalho, Mauricio, Ravaioli, Matteo, Caicedo, Juan Carlos, Loss, George, Lucidi, Valerio, Sapisochin, Gonzalo, Romagnoli, Renato, Jassem, Wayel, Colledan, Michele, De Carlis, Luciano, Rossi, Giorgio, Di Benedetto, Fabrizio, Miller, Charles M, van Hoek, Bart, Attia, Magdy, Lodge, Peter, Hernandez-Alejandro, Roberto, Detry, Olivier, Quintini, Cristiano, Oniscu, Gabriel C, Fondevila, Constantino, Malagó, Massimo, Pirenne, Jacques, IJzermans, Jan Nm, Porte, Robert J, Dutkowski, Philipp, Taner, C Burcin, Heaton, Nigel, Clavien, Pierre-Alain, Polak, Wojciech G, Muiesan, Paolo, Schlegel, A, van Reeven, M, Croome, K, Parente, A, Dolcet, A, Widmer, J, Meurisse, N, De Carlis, R, Hessheimer, A, Jochmans, I, Mueller, M, van Leeuwen, O, Nair, A, Tomiyama, K, Sherif, A, Elsharif, M, Kron, P, van der Helm, D, Borja-Cacho, D, Bohorquez, H, Germanova, D, Dondossola, D, Olivieri, T, Camagni, S, Gorgen, A, Patrono, D, Cescon, M, Croome, S, Panconesi, R, Flores Carvalho, M, Ravaioli, M, Caicedo, J, Loss, G, Lucidi, V, Sapisochin, G, Romagnoli, R, Jassem, W, Colledan, M, De Carlis, L, Rossi, G, Di Benedetto, F, Miller, C, van Hoek, B, Attia, M, Lodge, P, Hernandez-Alejandro, R, Detry, O, Quintini, C, Oniscu, G, Fondevila, C, Malagó, M, Pirenne, J, Ijzermans, J, Porte, R, Dutkowski, P, Taner, C, Heaton, N, Clavien, P, Polak, W, Muiesan, P, Schlegel, Andrea, van Reeven, Marjolein, Croome, Kristopher, Parente, Alessandro, Dolcet, Annalisa, Widmer, Jeannette, Meurisse, Nicolas, De Carlis, Riccardo, Hessheimer, Amelia, Jochmans, Ina, Mueller, Matteo, van Leeuwen, Otto B, Nair, Amit, Tomiyama, Koji, Sherif, Ahmed, Elsharif, Mohamed, Kron, Philipp, van der Helm, Danny, Borja-Cacho, Daniel, Bohorquez, Humberto, Germanova, Desislava, Dondossola, Daniele, Olivieri, Tiziana, Camagni, Stefania, Gorgen, Andre, Patrono, Damiano, Cescon, Matteo, Croome, Sarah, Panconesi, Rebecca, Flores Carvalho, Mauricio, Ravaioli, Matteo, Caicedo, Juan Carlos, Loss, George, Lucidi, Valerio, Sapisochin, Gonzalo, Romagnoli, Renato, Jassem, Wayel, Colledan, Michele, De Carlis, Luciano, Rossi, Giorgio, Di Benedetto, Fabrizio, Miller, Charles M, van Hoek, Bart, Attia, Magdy, Lodge, Peter, Hernandez-Alejandro, Roberto, Detry, Olivier, Quintini, Cristiano, Oniscu, Gabriel C, Fondevila, Constantino, Malagó, Massimo, Pirenne, Jacques, IJzermans, Jan Nm, Porte, Robert J, Dutkowski, Philipp, Taner, C Burcin, Heaton, Nigel, Clavien, Pierre-Alain, Polak, Wojciech G, and Muiesan, Paolo
Abstract: Background & Aims: The concept of benchmarking is established in the field of transplant surgery; however, benchmark values for donation after circulatory death (DCD) liver transplantation are not available. Thus, we aimed to identify the best possible outcomes in DCD liver transplantation and to propose outcome reference values. Methods: Based on 2,219 controlled DCD liver transplantations, collected from 17 centres in North America and Europe, we identified 1,012 low-risk, primary, adult liver transplantations with a laboratory MELD score of ≤20 points, receiving a DCD liver with a total donor warm ischemia time of ≤30 minutes and asystolic donor warm ischemia time of ≤15 minutes. Clinically relevant outcomes were selected and complications were reported according to the Clavien-Dindo-Grading and the comprehensive complication index (CCI). Corresponding benchmark cut-offs were based on median values of each centre, where the 75th-percentile was considered. Results: Benchmark cases represented between 19.7% and 75% of DCD transplantations in participating centres. The 1-year retransplant and mortality rates were 4.5% and 8.4% in the benchmark group, respectively. Within the first year of follow-up, 51.1% of recipients developed at least 1 major complication (≥Clavien-Dindo-Grade III). Benchmark cut-offs were ≤3 days and ≤16 days for ICU and hospital stay, ≤66% for severe recipient complications (≥Grade III), ≤16.8% for ischemic cholangiopathy, and ≤38.9 CCI points 1 year after transplant. Comparisons with higher risk groups showed more complications and impaired graft survival outside the benchmark cut-offs. Organ perfusion techniques reduced the complications to values below benchmark cut-offs, despite higher graft risk. Conclusions: Despite excellent 1-year survival, morbidity in benchmark cases remains high. Benchmark cut-offs targeting morbidity parameters offer a valid tool to assess the protective value of new preservation technologies in higher risk grou
Published: 2022

11. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

Author: Zorgeenheid Orthopaedie Medisch, MS Radiologie, MS CGO, Regenerative Medicine and Stem Cells, Cancer, Other research (not in main researchprogram), Experimentele Afdeling Longziekten, Korenblik, R, Olij, B, Aldrighetti, L A, Hilal, M Abu, Ahle, M, Arslan, B, van Baardewijk, L J, Baclija, I, Bent, C, Bertrand, C L, Björnsson, B, de Boer, M T, de Boer, S W, Bokkers, R P H, Rinkes, I H M Borel, Breitenstein, S, Bruijnen, R C G, Bruners, P, Büchler, M W, Camacho, J C, Cappelli, A, Carling, U, Chan, B K Y, Chang, D H, Choi, J, Font, J Codina, Crawford, M, Croagh, D, Cugat, E, Davis, R, De Boo, D W, De Cobelli, F, De Wispelaere, J F, van Delden, O M, Delle, M, Detry, O, Díaz-Nieto, R, Dili, A, Erdmann, J I, Fisher, O, Fondevila, C, Fretland, Å, Borobia, F Garcia, Gelabert, A, Gérard, L, Giuliante, F, Gobardhan, P D, Gómez, F, Grünberger, T, Grünhagen, D J, Guitart, J, Hagendoorn, J, Heil, J, Heise, D, Herrero, E, Hess, G F, Hoffmann, M H, Iezzi, R, Imani, F, Nguyen, J, Jovine, E, Kalff, J C, Kazemier, G, Kingham, T P, Kleeff, J, Kollmar, O, Leclercq, W K G, Ben, S Lopez, Lucidi, V, MacDonald, A, Madoff, D C, Manekeller, S, Martel, G, Mehrabi, A, Mehrzad, H, Meijerink, M R, Menon, K, Metrakos, P, Meyer, C, Moelker, A, Modi, S, Montanari, N, Navines, J, Neumann, U P, Peddu, P, Primrose, J N, Qu, X, Raptis, D, Ratti, F, Ridouani, F, Rogan, C, Ronellenfitsch, U, Ryan, S, Sallemi, C, Moragues, J Sampere, Sandström, P, Sarriá, L, Schnitzbauer, A, Serenari, M, Serrablo, A, Smits, M L J, Sparrelid, E, Spüntrup, E, Stavrou, G A, Sutcliffe, R P, Tancredi, I, Tasse, J C, Udupa, V, Valenti, D, Fundora, Y, Vogl, T J, Wang, X, White, S A, Wohlgemuth, W A, Yu, D, Zijlstra, I A J, Binkert, C A, Bemelmans, M H A, van der Leij, C, Schadde, E, van Dam, R M, Zorgeenheid Orthopaedie Medisch, MS Radiologie, MS CGO, Regenerative Medicine and Stem Cells, Cancer, Other research (not in main researchprogram), Experimentele Afdeling Longziekten, Korenblik, R, Olij, B, Aldrighetti, L A, Hilal, M Abu, Ahle, M, Arslan, B, van Baardewijk, L J, Baclija, I, Bent, C, Bertrand, C L, Björnsson, B, de Boer, M T, de Boer, S W, Bokkers, R P H, Rinkes, I H M Borel, Breitenstein, S, Bruijnen, R C G, Bruners, P, Büchler, M W, Camacho, J C, Cappelli, A, Carling, U, Chan, B K Y, Chang, D H, Choi, J, Font, J Codina, Crawford, M, Croagh, D, Cugat, E, Davis, R, De Boo, D W, De Cobelli, F, De Wispelaere, J F, van Delden, O M, Delle, M, Detry, O, Díaz-Nieto, R, Dili, A, Erdmann, J I, Fisher, O, Fondevila, C, Fretland, Å, Borobia, F Garcia, Gelabert, A, Gérard, L, Giuliante, F, Gobardhan, P D, Gómez, F, Grünberger, T, Grünhagen, D J, Guitart, J, Hagendoorn, J, Heil, J, Heise, D, Herrero, E, Hess, G F, Hoffmann, M H, Iezzi, R, Imani, F, Nguyen, J, Jovine, E, Kalff, J C, Kazemier, G, Kingham, T P, Kleeff, J, Kollmar, O, Leclercq, W K G, Ben, S Lopez, Lucidi, V, MacDonald, A, Madoff, D C, Manekeller, S, Martel, G, Mehrabi, A, Mehrzad, H, Meijerink, M R, Menon, K, Metrakos, P, Meyer, C, Moelker, A, Modi, S, Montanari, N, Navines, J, Neumann, U P, Peddu, P, Primrose, J N, Qu, X, Raptis, D, Ratti, F, Ridouani, F, Rogan, C, Ronellenfitsch, U, Ryan, S, Sallemi, C, Moragues, J Sampere, Sandström, P, Sarriá, L, Schnitzbauer, A, Serenari, M, Serrablo, A, Smits, M L J, Sparrelid, E, Spüntrup, E, Stavrou, G A, Sutcliffe, R P, Tancredi, I, Tasse, J C, Udupa, V, Valenti, D, Fundora, Y, Vogl, T J, Wang, X, White, S A, Wohlgemuth, W A, Yu, D, Zijlstra, I A J, Binkert, C A, Bemelmans, M H A, van der Leij, C, Schadde, E, and van Dam, R M
Published: 2022

12. Post cholecystectomy bile duct injury : early, intermediate or late repair with hepaticojejunostomy - an E-AHPBA multi-center study

Author: Rystedt, Jenny M. L., Kleeff, Joerg, Salvia, Roberto, Besselink, Mark G., Prasad, Raj, Lesurtel, Mickael, Sturesson, Christian, Abu Hilal, M., Aljaiuossi, A., Antonucci, A., Ardito, F., Ausania, F., Bernon, M., Berrevoet, F., Bjornsson, B., Bonsing, B. A., Boonstra, E. A., Bracke, B., Brusadin, R., Burda, L., Caraballo, M., Casellas-Robert, M., Coker, A., Davide, J., De Gelder, A., De Rose, A. M., Djokic, M., Dudek, K., Ekmekcigil, E., Filauro, M., Fulop, A., Gallagher, T. K., Gastaca, M., Gefen, R., Giuliante, F., Habibeh, H., Halle-Smith, J., Haraldsdottir, K. H., Hartman, V, Hauer, A., Hemmingsson, O., Hoskovec, D., Isaksson, Bengt, Jonas, E., A, Khalaileh, Klug, R., Krige, J., Lignier, D., Lindemann, J., Lopez-Lopez, V, Lucidi, V, Mabrut, J-Y, Månsson, Christopher, Mieog, S., Mirza, D. F., Oldhafer, K. J., Omoshoro-Jones, J. A. O., Ortega-Torrecilla, N., Otto, W., Panaro, F., Pando, E., Paterna-Lopez, S., Pekmezci, S., Pesce, A., Porte, R. J., Poves, I, Prieto Calvo, M., Primavesi, F., Puleo, S., Recordare, A., Rizell, M., Roberts, K., Robles-Campos, R., Sanchiz-Cardenas, E., Sandstrom, P., Saribeyoglu, K., Schauer, M., Schreuder, M., Siriwardena, A. K., Smith, M. D., Silva, Sousa D., Sparrelid, E., Staettner, S., Stavrou, G. A., Straka, M., Stromberg, C., Sutcliffe, R. P., Szijarto, A., Taflin, H., Trotovsek, B., van Gulik, T., Wallach, N., Zieniewicz, K., Rystedt, Jenny M. L., Kleeff, Joerg, Salvia, Roberto, Besselink, Mark G., Prasad, Raj, Lesurtel, Mickael, Sturesson, Christian, Abu Hilal, M., Aljaiuossi, A., Antonucci, A., Ardito, F., Ausania, F., Bernon, M., Berrevoet, F., Bjornsson, B., Bonsing, B. A., Boonstra, E. A., Bracke, B., Brusadin, R., Burda, L., Caraballo, M., Casellas-Robert, M., Coker, A., Davide, J., De Gelder, A., De Rose, A. M., Djokic, M., Dudek, K., Ekmekcigil, E., Filauro, M., Fulop, A., Gallagher, T. K., Gastaca, M., Gefen, R., Giuliante, F., Habibeh, H., Halle-Smith, J., Haraldsdottir, K. H., Hartman, V, Hauer, A., Hemmingsson, O., Hoskovec, D., Isaksson, Bengt, Jonas, E., A, Khalaileh, Klug, R., Krige, J., Lignier, D., Lindemann, J., Lopez-Lopez, V, Lucidi, V, Mabrut, J-Y, Månsson, Christopher, Mieog, S., Mirza, D. F., Oldhafer, K. J., Omoshoro-Jones, J. A. O., Ortega-Torrecilla, N., Otto, W., Panaro, F., Pando, E., Paterna-Lopez, S., Pekmezci, S., Pesce, A., Porte, R. J., Poves, I, Prieto Calvo, M., Primavesi, F., Puleo, S., Recordare, A., Rizell, M., Roberts, K., Robles-Campos, R., Sanchiz-Cardenas, E., Sandstrom, P., Saribeyoglu, K., Schauer, M., Schreuder, M., Siriwardena, A. K., Smith, M. D., Silva, Sousa D., Sparrelid, E., Staettner, S., Stavrou, G. A., Straka, M., Stromberg, C., Sutcliffe, R. P., Szijarto, A., Taflin, H., Trotovsek, B., van Gulik, T., Wallach, N., and Zieniewicz, K.
Abstract: Background: Treatment of bile duct injuries (BDI) during cholecystectomy depends on the severity of injury and the timing of diagnosis. Standard of care for severe BDIs is hepaticojejunostomy. The aim of this retrospective multi-center study was to assess the optimal timing for repair of BDI with hepaticojejunostomy. Methods: Members of the European-African HepatoPancreatoBiliary Association were invited to report all consecutive patients with hepaticojejunostomy after BDI from January 2000 to June 2016. Patients were stratified according to the timing of biliary reconstruction with hepaticojejunostomy: early (day 0–7), intermediate (1–6 weeks) and late (6 weeks–6 months). Primary endpoint was re-intervention >90 days after the hepaticojejunostomy and secondary endpoints were severe 90-day complications and liver-related mortality. Results: In total 913 patients from 48 centers were included in the analysis. In 401 patients (44%) the bile duct injury was diagnosed intraoperatively, and 126 patients (14%) suffered from concomitant vascular injury. In multivariable analysis the timing of hepaticojejunostomy had no impact on postoperative complications, the need for re-intervention after 90 days nor liver-related mortality. The rate of re-intervention more than 90 days after the hepaticojejunostomy was significantly increased in male patients but decreased in older patients. Severe co-morbidity increased the risk for liver-related mortality (HR 3.439; CI 1.37–8.65; p = 0.009). Conclusion: After BDI occurring during cholecystectomy, the timing of biliary reconstruction with hepaticojejunostomy did not have any impact on severe postoperative complications, the need for re-intervention or liver-related mortality. Individualised treatment after iatrogenic bile duct injury is still advisable.
Published: 2019
Full Text: View/download PDF

13. Post cholecystectomy bile duct injury : early, intermediate or late repair with hepaticojejunostomy - an E-AHPBA multi-center study

Author: Rystedt, Jenny M. L., Kleeff, Joerg, Salvia, Roberto, Besselink, Mark G., Prasad, Raj, Lesurtel, Mickael, Sturesson, Christian, Abu Hilal, M., Aljaiuossi, A., Antonucci, A., Ardito, F., Ausania, F., Bernon, M., Berrevoet, F., Bjornsson, B., Bonsing, B. A., Boonstra, E. A., Bracke, B., Brusadin, R., Burda, L., Caraballo, M., Casellas-Robert, M., Coker, A., Davide, J., De Gelder, A., De Rose, A. M., Djokic, M., Dudek, K., Ekmekcigil, E., Filauro, M., Fulop, A., Gallagher, T. K., Gastaca, M., Gefen, R., Giuliante, F., Habibeh, H., Halle-Smith, J., Haraldsdottir, K. H., Hartman, V, Hauer, A., Hemmingsson, Oskar, Hoskovec, D., Isaksson, B., Jonas, E., A, Khalaileh, Klug, R., Krige, J., Lignier, D., Lindemann, J., Lopez-Lopez, V, Lucidi, V, Mabrut, J-Y, Mansson, C., Mieog, S., Mirza, D. F., Oldhafer, K. J., Omoshoro-Jones, J. A. O., Ortega-Torrecilla, N., Otto, W., Panaro, F., Pando, E., Paterna-Lopez, S., Pekmezci, S., Pesce, A., Porte, R. J., Poves, I, Prieto Calvo, M., Primavesi, F., Puleo, S., Recordare, A., Rizell, M., Roberts, K., Robles-Campos, R., Sanchiz-Cardenas, E., Sandstrom, P., Saribeyoglu, K., Schauer, M., Schreuder, M., Siriwardena, A. K., Smith, M. D., Silva, Sousa D., Sparrelid, E., Staettner, S., Stavrou, G. A., Straka, M., Stromberg, C., Sutcliffe, R. P., Szijarto, A., Taflin, H., Trotovsek, B., van Gulik, T., Wallach, N., Zieniewicz, K., Rystedt, Jenny M. L., Kleeff, Joerg, Salvia, Roberto, Besselink, Mark G., Prasad, Raj, Lesurtel, Mickael, Sturesson, Christian, Abu Hilal, M., Aljaiuossi, A., Antonucci, A., Ardito, F., Ausania, F., Bernon, M., Berrevoet, F., Bjornsson, B., Bonsing, B. A., Boonstra, E. A., Bracke, B., Brusadin, R., Burda, L., Caraballo, M., Casellas-Robert, M., Coker, A., Davide, J., De Gelder, A., De Rose, A. M., Djokic, M., Dudek, K., Ekmekcigil, E., Filauro, M., Fulop, A., Gallagher, T. K., Gastaca, M., Gefen, R., Giuliante, F., Habibeh, H., Halle-Smith, J., Haraldsdottir, K. H., Hartman, V, Hauer, A., Hemmingsson, Oskar, Hoskovec, D., Isaksson, B., Jonas, E., A, Khalaileh, Klug, R., Krige, J., Lignier, D., Lindemann, J., Lopez-Lopez, V, Lucidi, V, Mabrut, J-Y, Mansson, C., Mieog, S., Mirza, D. F., Oldhafer, K. J., Omoshoro-Jones, J. A. O., Ortega-Torrecilla, N., Otto, W., Panaro, F., Pando, E., Paterna-Lopez, S., Pekmezci, S., Pesce, A., Porte, R. J., Poves, I, Prieto Calvo, M., Primavesi, F., Puleo, S., Recordare, A., Rizell, M., Roberts, K., Robles-Campos, R., Sanchiz-Cardenas, E., Sandstrom, P., Saribeyoglu, K., Schauer, M., Schreuder, M., Siriwardena, A. K., Smith, M. D., Silva, Sousa D., Sparrelid, E., Staettner, S., Stavrou, G. A., Straka, M., Stromberg, C., Sutcliffe, R. P., Szijarto, A., Taflin, H., Trotovsek, B., van Gulik, T., Wallach, N., and Zieniewicz, K.
Abstract: Background: Treatment of bile duct injuries (BDI) during cholecystectomy depends on the severity of injury and the timing of diagnosis. Standard of care for severe BDIs is hepaticojejunostomy. The aim of this retrospective multi-center study was to assess the optimal timing for repair of BDI with hepaticojejunostomy. Methods: Members of the European-African HepatoPancreatoBiliary Association were invited to report all consecutive patients with hepaticojejunostomy after BDI from January 2000 to June 2016. Patients were stratified according to the timing of biliary reconstruction with hepaticojejunostomy: early (day 0-7), intermediate (1-6 weeks) and late (6 weeks-6 months). Primary endpoint was re-intervention >90 days after the hepaticojejunostomy and secondary endpoints were severe 90-day complications and liver-related mortality. Results: In total 913 patients from 48 centers were included in the analysis. In 401 patients (44%) the bile duct injury was diagnosed intraoperatively, and 126 patients (14%) suffered from concomitant vascular injury. In multivariable analysis the timing of hepaticojejunostomy had no impact on postoperative complications, the need for re-intervention after 90 days nor liver-related mortality. The rate of re-intervention more than 90 days after the hepaticojejunostomy was significantly increased in male patients but decreased in older patients. Severe co-morbidity increased the risk for liver-related mortality (HR 3.439; CI 1.37-8.65; p = 0.009). Conclusion: After BDI occurring during cholecystectomy, the timing of biliary reconstruction with hepaticojejunostomy did not have any impact on severe postoperative complications, the need for re-intervention or liver-related mortality. Individualised treatment after iatrogenic bile duct injury is still advisable.
Published: 2019
Full Text: View/download PDF

14. Post cholecystectomy bile duct injury: early, intermediate or late repair with hepaticojejunostomy – an E-AHPBA multi-center study

Author: Rystedt, J. M. L., Kleeff, J., Salvia, R., Besselink, M. G., Prasad, R., Lesurtel, M., Sturesson, C., Abu Hilal, M., Aljaiuossi, A., Antonucci, A., Ardito, Francesco, Ausania, F., Bernon, M., Berrevoet, F., Bjornsson, B., Bonsing, B. A., Boonstra, E. A., Bracke, B., Brusadin, R., Burda, L., Caraballo, M., Casellas-Robert, M., Coker, A., Davide, J., De Gelder, A., De Rose, A. M., Djokic, M., Dudek, K., Ekmekcigil, E., Filauro, M., Fulop, A., Gallagher, T., Gastaca, M., Gefen, R., Giuliante, Felice, Habibeh, H., Halle-Smith, J., Haraldsdottir, K. H., Hartman, V., Hauer, A., Hemmingsson, O., Hoskovec, D., Isaksson, B., Jonas, E., Khalaileh, A., Klug, R., Krige, J., Lignier, D., Lindemann, J., Lopez-Lopez, V., Lucidi, V., Mabrut, J. -Y., Mansson, C., Mieog, S., Mirza, D. F., Oldhafer, K. J., Omoshoro-Jones, J. A. O., Ortega-Torrecilla, N., Otto, W., Panaro, F., Pando, E., Paterna-Lopez, S., Pekmezci, S., Pesce, A., Porte, R. J., Poves, I., Prieto Calvo, M., Primavesi, F., Puleo, S., Recordare, A., Rizell, M., Roberts, K., Robles-Campos, R., Sanchiz-Cardenas, E., Sandstrom, P., Saribeyoglu, K., Schauer, M., Schreuder, M., Siriwardena, A. K., Smith, M. D., Sousa Silva, D., Sparrelid, E., Stattner, S., Stavrou, G. A., Straka, M., Stromberg, C., Sutcliffe, R. P., Szijarto, A., Taflin, H., Trotovsek, B., van Gulik, T., Wallach, N., Zieniewicz, K., Ardito F. (ORCID:0000-0003-1596-2862), Giuliante F. (ORCID:0000-0001-9517-8220), Rystedt, J. M. L., Kleeff, J., Salvia, R., Besselink, M. G., Prasad, R., Lesurtel, M., Sturesson, C., Abu Hilal, M., Aljaiuossi, A., Antonucci, A., Ardito, Francesco, Ausania, F., Bernon, M., Berrevoet, F., Bjornsson, B., Bonsing, B. A., Boonstra, E. A., Bracke, B., Brusadin, R., Burda, L., Caraballo, M., Casellas-Robert, M., Coker, A., Davide, J., De Gelder, A., De Rose, A. M., Djokic, M., Dudek, K., Ekmekcigil, E., Filauro, M., Fulop, A., Gallagher, T., Gastaca, M., Gefen, R., Giuliante, Felice, Habibeh, H., Halle-Smith, J., Haraldsdottir, K. H., Hartman, V., Hauer, A., Hemmingsson, O., Hoskovec, D., Isaksson, B., Jonas, E., Khalaileh, A., Klug, R., Krige, J., Lignier, D., Lindemann, J., Lopez-Lopez, V., Lucidi, V., Mabrut, J. -Y., Mansson, C., Mieog, S., Mirza, D. F., Oldhafer, K. J., Omoshoro-Jones, J. A. O., Ortega-Torrecilla, N., Otto, W., Panaro, F., Pando, E., Paterna-Lopez, S., Pekmezci, S., Pesce, A., Porte, R. J., Poves, I., Prieto Calvo, M., Primavesi, F., Puleo, S., Recordare, A., Rizell, M., Roberts, K., Robles-Campos, R., Sanchiz-Cardenas, E., Sandstrom, P., Saribeyoglu, K., Schauer, M., Schreuder, M., Siriwardena, A. K., Smith, M. D., Sousa Silva, D., Sparrelid, E., Stattner, S., Stavrou, G. A., Straka, M., Stromberg, C., Sutcliffe, R. P., Szijarto, A., Taflin, H., Trotovsek, B., van Gulik, T., Wallach, N., Zieniewicz, K., Ardito F. (ORCID:0000-0003-1596-2862), and Giuliante F. (ORCID:0000-0001-9517-8220)
Abstract: Background: Treatment of bile duct injuries (BDI) during cholecystectomy depends on the severity of injury and the timing of diagnosis. Standard of care for severe BDIs is hepaticojejunostomy. The aim of this retrospective multi-center study was to assess the optimal timing for repair of BDI with hepaticojejunostomy. Methods: Members of the European-African HepatoPancreatoBiliary Association were invited to report all consecutive patients with hepaticojejunostomy after BDI from January 2000 to June 2016. Patients were stratified according to the timing of biliary reconstruction with hepaticojejunostomy: early (day 0–7), intermediate (1–6 weeks) and late (6 weeks–6 months). Primary endpoint was re-intervention >90 days after the hepaticojejunostomy and secondary endpoints were severe 90-day complications and liver-related mortality. Results: In total 913 patients from 48 centers were included in the analysis. In 401 patients (44%) the bile duct injury was diagnosed intraoperatively, and 126 patients (14%) suffered from concomitant vascular injury. In multivariable analysis the timing of hepaticojejunostomy had no impact on postoperative complications, the need for re-intervention after 90 days nor liver-related mortality. The rate of re-intervention more than 90 days after the hepaticojejunostomy was significantly increased in male patients but decreased in older patients. Severe co-morbidity increased the risk for liver-related mortality (HR 3.439; CI 1.37–8.65; p = 0.009). Conclusion: After BDI occurring during cholecystectomy, the timing of biliary reconstruction with hepaticojejunostomy did not have any impact on severe postoperative complications, the need for re-intervention or liver-related mortality. Individualised treatment after iatrogenic bile duct injury is still advisable.
Published: 2019

15. Streptococcus pneumoniae oropharyngeal colonization in children and adolescents with cystic fibrosis

Author: Esposito, S, Colombo, C, Tosco, A, Montemitro, E, Volpi, S, Ruggiero, L, Lelii, M, Bisogno, A, Pelucchi, C, Principi, N, Terranova, L, Zampiero, A, Montinaro, V, Ierardi, V, Gambino, M, Corti, F, Moresco, R, Raia, V, Impronta, F, Lucidi, V, Passiu, M, Meneghelli, I, Esposito S., Colombo C., Tosco A., Montemitro E., Volpi S., Ruggiero L., Lelii M., Bisogno A., Pelucchi C., Principi N., Terranova L., Zampiero A., Montinaro V., Ierardi V., Gambino M., Corti F., Moresco R., Raia V., Impronta F., Lucidi V., Passiu M., Meneghelli I., Esposito, S, Colombo, C, Tosco, A, Montemitro, E, Volpi, S, Ruggiero, L, Lelii, M, Bisogno, A, Pelucchi, C, Principi, N, Terranova, L, Zampiero, A, Montinaro, V, Ierardi, V, Gambino, M, Corti, F, Moresco, R, Raia, V, Impronta, F, Lucidi, V, Passiu, M, Meneghelli, I, Esposito S., Colombo C., Tosco A., Montemitro E., Volpi S., Ruggiero L., Lelii M., Bisogno A., Pelucchi C., Principi N., Terranova L., Zampiero A., Montinaro V., Ierardi V., Gambino M., Corti F., Moresco R., Raia V., Impronta F., Lucidi V., Passiu M., and Meneghelli I.
Abstract: Background: This study was designed to evaluate Streptococcus pneumoniae (S. pneumoniae) carriage rates in patients with cystic fibrosis (CF). Methods: An oropharyngeal swab was obtained from 212 CF children and adolescents enrolled during routine clinical visits. DNA from swabs was analyzed by real-time polymerase chain reaction. Results: A total of 42 (19.8%) CF patients (mean age ± standard deviation [SD], 12.0 ± 3.3 years) were colonized by S. pneumoniae. Carriage was more common in younger patients and tended to decline with age. Administration of systemic and/or inhaled antibiotics in the last 3 months significantly correlated with a reduced carrier state [odds ratio (OR) 0.23, 95% confidence interval (CI) 0.07-0.69, and OR 0.26, 95% CI 0.08-0.77, respectively]. Vitamin D serum levels ≥. 30 ng/mL were less common in carriers than that in non-carriers (OR 0.35; 95% CI 0.08-1.49). In both the vaccinated and unvaccinated subjects, serotypes 19F, 5, 4, and 9V were the most commonly carried serotypes. Conclusions: S. pneumoniae carrier state of school-age children and adolescents with CF is more prevalent than previously thought, and pneumococcal conjugate vaccination administered in the first year of life does not reduce the risk of re-colonization in later childhood and adolescence.
Published: 2016

16. Streptococcus pneumoniae oropharyngeal colonization in children and adolescents with cystic fibrosis

Author: Esposito, S, Colombo, C, Tosco, A, Montemitro, E, Volpi, S, Ruggiero, L, Lelii, M, Bisogno, A, Pelucchi, C, Principi, N, Terranova, L, Zampiero, A, Montinaro, V, Ierardi, V, Gambino, M, Corti, F, Moresco, R, Raia, V, Impronta, F, Lucidi, V, Passiu, M, Meneghelli, I, Esposito S., Colombo C., Tosco A., Montemitro E., Volpi S., Ruggiero L., Lelii M., Bisogno A., Pelucchi C., Principi N., Terranova L., Zampiero A., Montinaro V., Ierardi V., Gambino M., Corti F., Moresco R., Raia V., Impronta F., Lucidi V., Passiu M., Meneghelli I., Esposito, S, Colombo, C, Tosco, A, Montemitro, E, Volpi, S, Ruggiero, L, Lelii, M, Bisogno, A, Pelucchi, C, Principi, N, Terranova, L, Zampiero, A, Montinaro, V, Ierardi, V, Gambino, M, Corti, F, Moresco, R, Raia, V, Impronta, F, Lucidi, V, Passiu, M, Meneghelli, I, Esposito S., Colombo C., Tosco A., Montemitro E., Volpi S., Ruggiero L., Lelii M., Bisogno A., Pelucchi C., Principi N., Terranova L., Zampiero A., Montinaro V., Ierardi V., Gambino M., Corti F., Moresco R., Raia V., Impronta F., Lucidi V., Passiu M., and Meneghelli I.
Abstract: Background: This study was designed to evaluate Streptococcus pneumoniae (S. pneumoniae) carriage rates in patients with cystic fibrosis (CF). Methods: An oropharyngeal swab was obtained from 212 CF children and adolescents enrolled during routine clinical visits. DNA from swabs was analyzed by real-time polymerase chain reaction. Results: A total of 42 (19.8%) CF patients (mean age ± standard deviation [SD], 12.0 ± 3.3 years) were colonized by S. pneumoniae. Carriage was more common in younger patients and tended to decline with age. Administration of systemic and/or inhaled antibiotics in the last 3 months significantly correlated with a reduced carrier state [odds ratio (OR) 0.23, 95% confidence interval (CI) 0.07-0.69, and OR 0.26, 95% CI 0.08-0.77, respectively]. Vitamin D serum levels ≥. 30 ng/mL were less common in carriers than that in non-carriers (OR 0.35; 95% CI 0.08-1.49). In both the vaccinated and unvaccinated subjects, serotypes 19F, 5, 4, and 9V were the most commonly carried serotypes. Conclusions: S. pneumoniae carrier state of school-age children and adolescents with CF is more prevalent than previously thought, and pneumococcal conjugate vaccination administered in the first year of life does not reduce the risk of re-colonization in later childhood and adolescence.
Published: 2016

17. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis

Author: Montuschi, P, Lucidi, V, Paris, D, Montemitro, E, Shohreh, R, Mores, N, Melck, D, Santini, G, Majo, F, Motta, A, Montuschi P (ORCID:0000-0001-5589-1750), Mores N (ORCID:0000-0002-4197-0914), Santini G, Montuschi, P, Lucidi, V, Paris, D, Montemitro, E, Shohreh, R, Mores, N, Melck, D, Santini, G, Majo, F, Motta, A, Montuschi P (ORCID:0000-0001-5589-1750), Mores N (ORCID:0000-0002-4197-0914), and Santini G
Abstract: 15-F2t-Isoprostane, a reliable biomarker of oxidative stress, has been found elevated in exhaled breath condensate (EBC), a non-invasive technique for sampling of airway secretions, in patients with cystic fibrosis (CF). Azithromycin has antioxidant properties in experimental models of CF, but its effects on oxidative stress in CF patients are largely unknown. Primary objective of this pilot, proof-of-concept, prospective, parallel group, pharmacological study, was investigating the potential antioxidant effects of azithromycin in CF patients as reflected by EBC 15-F2t-isoprostane. Secondary objectives included studying the effect of azithromycin on EBC and serum metabolic profiles, and on serum 15-F2t-isoprostane. In CF patients who were on maintenance treatment with oral vitamin E (200 UI once daily), treatment with oral azithromycin (250 or 500 mg depending on body weight) plus vitamin E (400 UI once daily) (group A) (n = 24) or oral vitamin E alone (400 UI once daily) (group B) (n = 21) was not associated with changes in EBC 15-F2t-isoprostane compared with baseline values after 8–week treatment or 2 weeks after treatment suspension. Likewise, no within- or between-group differences on serum 15-F2t-isoprostane or metabolites were observed in both study groups. NMR spectroscopy-based metabolomics of EBC shows that suspension of both azithromycin plus vitamin E and vitamin E alone has a striking effect on metabolic profiles in EBC. Between-group comparisons show that EBC metabolite distribution after treatment and two weeks after treatment suspension is different. Quantitative differences in ethanol, saturated fatty acids, acetate, acetoin/acetone, and methanol are responsible for these differences. Our study was unable to show antioxidant effect of azithromicyn as add-on treatment with doubling the dose of oral vitamin E as reflected by 15-F2t-isoprostane concentrations in EBC. Add-on therapy with azithromycin itself does not induce EBC metabolite changes, but it
Published: 2018

18. Implementing carrier screening for cystic fibrosis outside the clinic: ethical analysis in the light of the personalist view

Author: Di Pietro, Maria Luisa, Teleman, Adele Anna, GONZALEZ-MELADO, Fj, Zace, Drieda, Di Raimo, Francesca Romana, Lucidi, V, Refolo, Pietro, DI PIETRO ML (ORCID:0000-0002-3893-8788), TELEMAN AA, DI RAIMO FR, REFOLO P (ORCID:0000-0003-1055-160X), Di Pietro, Maria Luisa, Teleman, Adele Anna, GONZALEZ-MELADO, Fj, Zace, Drieda, Di Raimo, Francesca Romana, Lucidi, V, Refolo, Pietro, DI PIETRO ML (ORCID:0000-0002-3893-8788), TELEMAN AA, DI RAIMO FR, and REFOLO P (ORCID:0000-0003-1055-160X)
Abstract: Background. Cystic Fibrosis (CF) is an autosomal recessive genetic disease. Two models for screening CF are normally used: newborn screening and population-based CF carrier screening. In turn, there are three main models of population-based CF carrier screening: prenatal carrier screening, preconception carrier screening, and carrier screening outside clinical settings. Aim. To evaluate, in the light of the personalist view, the use of carrier screenings for CF outside the clinic, i.e. in non-clinical settings, such as school and workplaces.Methods. Analysis has been carried out according to the “Perso-nalist approach” (also called “Triangular model”), an ethical method for performing ethical analysis within HTA process. It includes factual, anthropological and ethical data in a ‘‘triangular’’ normative reflection process.Findings. Implementing carrier screening for cystic fibrosis outside the clinical settings allows acquisition of knowledge for informing reproductive choices, that can be considered as valuable; benefit-risk ratio seems to be not much favorable; autonomous and responsible decisions can be taken only under certain conditions; economic ad-vantage is difficult to determine; therefore, from a personalist view, implementing carrier screenings outside the clinic seems not to be ethically justified. Conclusion. In accordance with the personalist perspective, public health programs providing carrier screenings outside the clinic should not be implemented.
Published: 2018

19. Long-term outcomes of patients with 10 or more colorectal liver metastases

Author: Allard, M.A. (M. A.), Adam, R. (René), Giuliante, F. (Felice), Lapointe, R. (R.), Hubert, C. (Catherine), IJzermans, J.N.M. (Jan), Mirza, D.F. (Darius), Elias, D. (Dominique), Laurent, C. (Christophe), Gruenberger, T. (Thomas), Poston, L. (Lucilla), Letoublon, C. (Christian), Isoniemi, H. (Helena), Lucidi, V. (Valerio), Popescu, I. (I.), Figueras, J., Allard, M.A. (M. A.), Adam, R. (René), Giuliante, F. (Felice), Lapointe, R. (R.), Hubert, C. (Catherine), IJzermans, J.N.M. (Jan), Mirza, D.F. (Darius), Elias, D. (Dominique), Laurent, C. (Christophe), Gruenberger, T. (Thomas), Poston, L. (Lucilla), Letoublon, C. (Christian), Isoniemi, H. (Helena), Lucidi, V. (Valerio), Popescu, I. (I.), and Figueras, J.
Abstract: Although the number of colorectal liver metastases (CLM) is decreasingly considered as a contraindication to surgery, patients with 10 CLM or more are often denied liver surgery. This study aimed to evaluate the outcome after liver surgery and to identify prognostic factors of survival in such patients.Methods:The study population consisted of a multicentre cohort of patients with CLM (N=12 406) operated on, with intention to resect, from January 2005-June 2013 and whose data were prospectively collected in the LiverMetSurvey registry.Results:Overall, the group â(c) 3/410 CLM (N=529, 4.3%) experienced a 5-year overall survival (OS) of 30%. A macroscopically complete (R0/R1) resection (72.8% of patients) was associated with a 3- A nd 5-year OS of 61% and 39% vs 29% and 5% for R2/no resection patients (P<0.0001). At multivariate analysis, R0/R1 resection emerged as the strongest favourable factor of OS (HR 0.35 (0.26-0.48)). Other independent favourable factors were as follows: Maximal tumour size <40 mm (HR 0.67 (0.49-0.92)); age <60 years (HR 0.66 (0.50-0.88)); preoperative MRI (HR 0.65 (0.47-0.89)); and adjuvant chemotherapy (HR 0.73 (0.55-0.98)). The model showed that 5-year OS rates of 30% was possible provided R0/R1 resection associated with at least an additional favourable factor.Conclusions:Liver resection might provide long-term survival in patients with â(c) 3/410 CLM staged with preoperative MRI, provided R0/R1 resection followed by adjuvant therapy. A validation of these results in another cohort is needed.
Published: 2017
Full Text: View/download PDF

20. Technical Aspects of Liver Transplantation - A Survey-Based Study within the Eurotransplant, Swisstransplant, Scandiatransplant and British Transplantation Society Networks

Author: Czigany, Z., Schoening, W., Ulmer, T. F., Bednarsch, J., Schnitzbauer, A., Scherer, M. N., Guba, M., Klempnauer, J., Nadalin, S., Herden, U., Lang, H., Paul, A., Pratschke, J., Seehofer, D., Glanemann, M., Braun, F., Senninger, N., Settmacher, U., Bruns, C., Mehrabi, A., Pirenne, J., Berlakovich, G. A., Schneeberger, S., Rogiers, X., Lucidi, V., Meurisse, M., Skegro, M., Mathe, Z., Veselko, M., Tomazic, A., Dutkowski, P., Banz-Wuethrich, V., Line, P. -D., Ericzon, B. -G., Malago, M., Heaton, N., Neumann, U. P., Lurje, G., Czigany, Z., Schoening, W., Ulmer, T. F., Bednarsch, J., Schnitzbauer, A., Scherer, M. N., Guba, M., Klempnauer, J., Nadalin, S., Herden, U., Lang, H., Paul, A., Pratschke, J., Seehofer, D., Glanemann, M., Braun, F., Senninger, N., Settmacher, U., Bruns, C., Mehrabi, A., Pirenne, J., Berlakovich, G. A., Schneeberger, S., Rogiers, X., Lucidi, V., Meurisse, M., Skegro, M., Mathe, Z., Veselko, M., Tomazic, A., Dutkowski, P., Banz-Wuethrich, V., Line, P. -D., Ericzon, B. -G., Malago, M., Heaton, N., Neumann, U. P., and Lurje, G.
Published: 2017

21. Technical Aspects of Liver Transplantation - A Survey-Based Study within the Eurotransplant, Swisstransplant, Scandiatransplant and British Transplantation Society Networks

Author: Czigany, Z., Schoening, W., Ulmer, T. F., Bednarsch, J., Schnitzbauer, A., Scherer, M. N., Guba, M., Klempnauer, J., Nadalin, S., Herden, U., Lang, H., Paul, A., Pratschke, J., Seehofer, D., Glanemann, M., Braun, F., Senninger, N., Settmacher, U., Bruns, C., Mehrabi, A., Pirenne, J., Berlakovich, G. A., Schneeberger, S., Rogiers, X., Lucidi, V., Meurisse, M., Skegro, M., Mathe, Z., Veselko, M., Tomazic, A., Dutkowski, P., Banz-Wuethrich, V., Line, P. -D., Ericzon, B. -G., Malago, M., Heaton, N., Neumann, U. P., Lurje, G., Czigany, Z., Schoening, W., Ulmer, T. F., Bednarsch, J., Schnitzbauer, A., Scherer, M. N., Guba, M., Klempnauer, J., Nadalin, S., Herden, U., Lang, H., Paul, A., Pratschke, J., Seehofer, D., Glanemann, M., Braun, F., Senninger, N., Settmacher, U., Bruns, C., Mehrabi, A., Pirenne, J., Berlakovich, G. A., Schneeberger, S., Rogiers, X., Lucidi, V., Meurisse, M., Skegro, M., Mathe, Z., Veselko, M., Tomazic, A., Dutkowski, P., Banz-Wuethrich, V., Line, P. -D., Ericzon, B. -G., Malago, M., Heaton, N., Neumann, U. P., and Lurje, G.
Published: 2017

22. Long-term outcomes of patients with 10 or more colorectal liver metastases

Author: Allard, MA, Adam, R, Giuliante, F, Lapointe, R, Hubert, C, IJzermans, J.N.M., Mirza, DF, Elias, D, Laurent, C, Gruenberger, T, Poston, G, Letoublon, C, Isoniemi, H, Lucidi, V, Popescu, I, Figueras, J, Allard, MA, Adam, R, Giuliante, F, Lapointe, R, Hubert, C, IJzermans, J.N.M., Mirza, DF, Elias, D, Laurent, C, Gruenberger, T, Poston, G, Letoublon, C, Isoniemi, H, Lucidi, V, Popescu, I, and Figueras, J
Published: 2017

23. IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis

Author: Iannitti, R.G., Napolioni, V., Oikonomou, V., Luca, A. De, Galosi, C., Pariano, M., Massi-Benedetti, C., Borghi, M., Puccetti, M., Lucidi, V., Colombo, C., Fiscarelli, E., Lass-Florl, C., Majo, F., Cariani, L., Russo, M., Porcaro, L., Ricciotti, G., Ellemunter, H., Ratclif, L., Benedictis, F.M. De, Talesa, V.N., Dinarello, C.A., Veerdonk, F.L. van de, Romani, L., Iannitti, R.G., Napolioni, V., Oikonomou, V., Luca, A. De, Galosi, C., Pariano, M., Massi-Benedetti, C., Borghi, M., Puccetti, M., Lucidi, V., Colombo, C., Fiscarelli, E., Lass-Florl, C., Majo, F., Cariani, L., Russo, M., Porcaro, L., Ricciotti, G., Ellemunter, H., Ratclif, L., Benedictis, F.M. De, Talesa, V.N., Dinarello, C.A., Veerdonk, F.L. van de, and Romani, L.
Abstract: Contains fulltext : 172723.pdf (publisher's version ) (Open Access), Dysregulated inflammasome activation contributes to respiratory infections and pathologic airway inflammation. Through basic and translational approaches involving murine models and human genetic epidemiology, we show here the importance of the different inflammasomes in regulating inflammatory responses in mice and humans with cystic fibrosis (CF), a life-threatening disorder of the lungs and digestive system. While both contributing to pathogen clearance, NLRP3 more than NLRC4 contributes to deleterious inflammatory responses in CF and correlates with defective NLRC4-dependent IL-1Ra production. Disease susceptibility in mice and microbial colonization in humans occurrs in conditions of genetic deficiency of NLRC4 or IL-1Ra and can be rescued by administration of the recombinant IL-1Ra, anakinra. These results indicate that pathogenic NLRP3 activity in CF could be negatively regulated by IL-1Ra and provide a proof-of-concept evidence that inflammasomes are potential targets to limit the pathological consequences of microbial colonization in CF.
Published: 2016

24. IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis

Author: Iannitti, R.G., Napolioni, V., Oikonomou, V., Luca, A. De, Galosi, C., Pariano, M., Massi-Benedetti, C., Borghi, M., Puccetti, M., Lucidi, V., Colombo, C., Fiscarelli, E., Lass-Florl, C., Majo, F., Cariani, L., Russo, M., Porcaro, L., Ricciotti, G., Ellemunter, H., Ratclif, L., Benedictis, F.M. De, Talesa, V.N., Dinarello, C.A., Veerdonk, F.L. van de, Romani, L., Iannitti, R.G., Napolioni, V., Oikonomou, V., Luca, A. De, Galosi, C., Pariano, M., Massi-Benedetti, C., Borghi, M., Puccetti, M., Lucidi, V., Colombo, C., Fiscarelli, E., Lass-Florl, C., Majo, F., Cariani, L., Russo, M., Porcaro, L., Ricciotti, G., Ellemunter, H., Ratclif, L., Benedictis, F.M. De, Talesa, V.N., Dinarello, C.A., Veerdonk, F.L. van de, and Romani, L.
Abstract: Contains fulltext : 172723.pdf (publisher's version ) (Open Access), Dysregulated inflammasome activation contributes to respiratory infections and pathologic airway inflammation. Through basic and translational approaches involving murine models and human genetic epidemiology, we show here the importance of the different inflammasomes in regulating inflammatory responses in mice and humans with cystic fibrosis (CF), a life-threatening disorder of the lungs and digestive system. While both contributing to pathogen clearance, NLRP3 more than NLRC4 contributes to deleterious inflammatory responses in CF and correlates with defective NLRC4-dependent IL-1Ra production. Disease susceptibility in mice and microbial colonization in humans occurrs in conditions of genetic deficiency of NLRC4 or IL-1Ra and can be rescued by administration of the recombinant IL-1Ra, anakinra. These results indicate that pathogenic NLRP3 activity in CF could be negatively regulated by IL-1Ra and provide a proof-of-concept evidence that inflammasomes are potential targets to limit the pathological consequences of microbial colonization in CF.
Published: 2016

25. IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis

Author: Iannitti, R.G., Napolioni, V., Oikonomou, V., Luca, A. De, Galosi, C., Pariano, M., Massi-Benedetti, C., Borghi, M., Puccetti, M., Lucidi, V., Colombo, C., Fiscarelli, E., Lass-Florl, C., Majo, F., Cariani, L., Russo, M., Porcaro, L., Ricciotti, G., Ellemunter, H., Ratclif, L., Benedictis, F.M. De, Talesa, V.N., Dinarello, C.A., Veerdonk, F.L. van de, Romani, L., Iannitti, R.G., Napolioni, V., Oikonomou, V., Luca, A. De, Galosi, C., Pariano, M., Massi-Benedetti, C., Borghi, M., Puccetti, M., Lucidi, V., Colombo, C., Fiscarelli, E., Lass-Florl, C., Majo, F., Cariani, L., Russo, M., Porcaro, L., Ricciotti, G., Ellemunter, H., Ratclif, L., Benedictis, F.M. De, Talesa, V.N., Dinarello, C.A., Veerdonk, F.L. van de, and Romani, L.
Abstract: Contains fulltext : 172723.pdf (publisher's version ) (Open Access), Dysregulated inflammasome activation contributes to respiratory infections and pathologic airway inflammation. Through basic and translational approaches involving murine models and human genetic epidemiology, we show here the importance of the different inflammasomes in regulating inflammatory responses in mice and humans with cystic fibrosis (CF), a life-threatening disorder of the lungs and digestive system. While both contributing to pathogen clearance, NLRP3 more than NLRC4 contributes to deleterious inflammatory responses in CF and correlates with defective NLRC4-dependent IL-1Ra production. Disease susceptibility in mice and microbial colonization in humans occurrs in conditions of genetic deficiency of NLRC4 or IL-1Ra and can be rescued by administration of the recombinant IL-1Ra, anakinra. These results indicate that pathogenic NLRP3 activity in CF could be negatively regulated by IL-1Ra and provide a proof-of-concept evidence that inflammasomes are potential targets to limit the pathological consequences of microbial colonization in CF.
Published: 2016

26. Nuclear magnetic resonance-based metabolomics discriminates primary ciliary dyskinesia from cystic fibrosis

Author: Montuschi, Paolo, Paris, D, Montella, S, Melck, D, Mirra, V, Santini, G, Mores, Nadia, Montemitro, E, Majo, F, Lucidi, V, Bush, A, Motta, A, Santamaria, F., Montuschi, Paolo (ORCID:0000-0001-5589-1750), Mores, Nadia (ORCID:0000-0002-4197-0914), Montuschi, Paolo, Paris, D, Montella, S, Melck, D, Mirra, V, Santini, G, Mores, Nadia, Montemitro, E, Majo, F, Lucidi, V, Bush, A, Motta, A, Santamaria, F., Montuschi, Paolo (ORCID:0000-0001-5589-1750), and Mores, Nadia (ORCID:0000-0002-4197-0914)
Abstract: The respiratory phenotypes of cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) are different, with PCD showing much slower progression. Nuclear magnetic resonance (NMR)-based metabolomics of exhaled breath condensate (EBC) recognizes markers separating children with asthma or adults with chronic obstructive pulmonary disease from healthy subjects and unstable from stable CF. No NMR studies in PCD have been reported, and whether EBC metabolic profiles in PCD differ from CF is unknown. In thuis cross-sectional stud we aimed to determine if NMR might be useful in discriminating between PCD and CF and possibly identify selective metabolites accounting for their differing prognoses.
Published: 2014

27. NMR spectroscopy-based metabolomics of exhaled breath condensate in inflammatory respiratory diseases

Author: Montuschi, Paolo, Paris, D, Melck, D, Mondino, C, Mores, Nadia, Trove', Andrea, Fuso, Leonello, Lucidi, V, Macagno, Francesco, Motta, A., Montuschi, Paolo (ORCID:0000-0001-5589-1750), Mores, Nadia (ORCID:0000-0002-4197-0914), Fuso, Leonello (ORCID:0000-0002-1198-6712), Montuschi, Paolo, Paris, D, Melck, D, Mondino, C, Mores, Nadia, Trove', Andrea, Fuso, Leonello, Lucidi, V, Macagno, Francesco, Motta, A., Montuschi, Paolo (ORCID:0000-0001-5589-1750), Mores, Nadia (ORCID:0000-0002-4197-0914), and Fuso, Leonello (ORCID:0000-0002-1198-6712)
Abstract: NMR spectroscopy-based metabolomics of exhaled breath condensate in inflammatory respiratory diseases
Published: 2012

28. Acoustic radiation force impulse (ARFI) imaging with Virtual Touch Tissue Quantification in liver disease associated with cystic fibrosis in children

Author: Monti, L, Manco, Melania, Lo Zupone, Cristina, Latini, Alessandro, D'Andrea, Maria Luisa, Alghisi, F, Lucidi, V, Tomà, P, Bonomo, Lorenzo, Bonomo, Lorenzo (ORCID:0000-0001-5101-9367), Monti, L, Manco, Melania, Lo Zupone, Cristina, Latini, Alessandro, D'Andrea, Maria Luisa, Alghisi, F, Lucidi, V, Tomà, P, Bonomo, Lorenzo, and Bonomo, Lorenzo (ORCID:0000-0001-5101-9367)
Abstract: PURPOSE: Cystic-fibrosis-associated liver disease (CFLD) may lead to portal hypertension (PHT) and cirrhosis. Clinical signs and biochemistry of liver involvement are not discriminating. The aim of the study was to evaluate the performance of acoustic radiation force impulse (ARFI) with virtual tissue quantification in comparison with clinical signs, biochemistry and standard hepatic ultrasound (US) patterns. MATERIALS AND METHODS: Virtual Touch Tissue Quantification, an implementation of US ARFI with shear-wave velocity (SWV) measurements was used in 75 children with cystic fibrosis (CF) and suspected CFLD to quantify hepatic stiffness. In each patient, ten measurements of SWV were performed on the right hepatic lobe. Patients were also evaluated by standard diagnostic tools (standard US, liver- and lung function tests, oesophagogastroscopy). RESULTS: Among CF patients, median SWV was significantly higher in patients with clinical, biochemical and US signs of hepatic involvement than in patients without US evidence of liver disease 1.08 m/s [(95% confidence interval (CI), 1.02-1.14]. Median SWV values in patients with portal hypertension, splenomegaly and oesophageal varices were 1.30 (95% CI, 1.17-1.43), 1.54 (95% CI, 1.32-1.75) and 1.63 (95% CI, 1.26-1.99), respectively. Differences were significant (p<0.001). CONCLUSIONS: ARFI is an innovative screening technique able to help identify CFLD in children.
Published: 2012

29. Progression while receiving preoperative chemotherapy should snot be an absolute contraindication to liver resection for colorectal metastases

Author: Viganò, L, Capussotti, L, Barroso, E, Nuzzo, Gennaro, Laurent, C, Ijzermans, Jn, Gigot, Jf, Figueras, J, Gruenberger, T, Mirza, Df, Elias, D, Poston, G, Letoublon, C, Isoniemi, H, Herrera, J, Castro Sousa, F, Pardo, F, Lucidi, V, Popescu, I, Adam, R., Viganò, L, Capussotti, L, Barroso, E, Nuzzo, Gennaro, Laurent, C, Ijzermans, Jn, Gigot, Jf, Figueras, J, Gruenberger, T, Mirza, Df, Elias, D, Poston, G, Letoublon, C, Isoniemi, H, Herrera, J, Castro Sousa, F, Pardo, F, Lucidi, V, Popescu, I, and Adam, R.
Abstract: PURPOSE: Tumor progression while receiving neoadjuvant chemotherapy (PD) has been associated with poor outcome and is commonly considered a contraindication to liver resection (LR). This study aims to clarify in a large multicenter setting whether PD is always a contraindication to LR. METHODS: Data from the LiverMetSurvey international registry were analyzed. Patients undergoing LR for colorectal metastases without extrahepatic disease after neoadjuvant chemotherapy between 1990 and 2009 were reviewed. RESULTS: Among 2143 patients, PD occurred in 176 (8.2 %). Risk of progression was increased after 5-FU or irinotecan (22.7 % vs. 6.8 % after other regimens, p < 0.0001; 14.9 % vs. 7.2 %, p < 0.0001), while it was reduced after oxaliplatin (5.6 % vs. 12.0 %, p < 0.0001) and still diminished among patients receiving targeted therapies (2.6 %). PD was an independent prognostic factor of survival at multivariate analysis (35 % vs. 49 %, p = 0.0006). In the PD group, 3 independent prognostic factors were identified: carcinoembryonic antigen (CEA) ≥200 ng/mL (p = 0.003), >3 metastases (p = 0.028), and tumor diameter ≥50 mm (p = 0.002). A survival predictive model showed that patients without any risk factors had 5-year survival rates of 53.3 %; good survival results were still observed if metastases were >3 or ≥50 mm (29.9 and 19.1 %, respectively). On the contrary, survival was less than 10 % at 3 years in the presence of >1 prognostic factor or CEA of ≥200 ng/mL. CONCLUSIONS: PD is a negative prognostic factor, but it is not an absolute contraindication to LR. Patients with PD could be scheduled for LR except for those with >3 metastases and ≥50 mm, or CEA ≥200 ng/mL in whom further chemotherapy is recommended.
Published: 2012

30. Progression while Receiving Preoperative Chemotherapy Should Not Be an Absolute Contraindication to Liver Resection for Colorectal Metastases

Author: Viganò, L., Capussotti, L., Barroso, E., Nuzzo, Gennaro, Laurent, C., Ljzermans, Jn, Gigot, Jf, Figueras, J, Gruenberger, T., Mirza, Df, Elias, D., Poston, G., Letoublon, C., Isoniemi, H., Herrera, J., Castro Sousa, F., Pardo, F., Lucidi, V., Popescu, I., Adam, R., Viganò, L., Capussotti, L., Barroso, E., Nuzzo, Gennaro, Laurent, C., Ljzermans, Jn, Gigot, Jf, Figueras, J, Gruenberger, T., Mirza, Df, Elias, D., Poston, G., Letoublon, C., Isoniemi, H., Herrera, J., Castro Sousa, F., Pardo, F., Lucidi, V., Popescu, I., and Adam, R.
Abstract: Progression while Receiving Preoperative Chemotherapy Should Not Be an Absolute Contraindication to Liver Resection for Colorectal Metastases. Viganò L, Capussotti L, Barroso E, Nuzzo G, Laurent C, Ijzermans JN, Gigot JF, Figueras J, Gruenberger T, Mirza DF, Elias D, Poston G, Letoublon C, Isoniemi H, Herrera J, Castro Sousa F, Pardo F, Lucidi V, Popescu I, Adam R. SourceDepartment of HPB and Digestive Surgery, Ospedale Mauriziano Umberto I, Turin, Italy. Abstract PURPOSE: Tumor progression while receiving neoadjuvant chemotherapy (PD) has been associated with poor outcome and is commonly considered a contraindication to liver resection (LR). This study aims to clarify in a large multicenter setting whether PD is always a contraindication to LR. METHODS: Data from the LiverMetSurvey international registry were analyzed. Patients undergoing LR for colorectal metastases without extrahepatic disease after neoadjuvant chemotherapy between 1990 and 2009 were reviewed. RESULTS: Among 2143 patients, PD occurred in 176 (8.2 %). Risk of progression was increased after 5-FU or irinotecan (22.7 % vs. 6.8 % after other regimens, p < 0.0001; 14.9 % vs. 7.2 %, p < 0.0001), while it was reduced after oxaliplatin (5.6 % vs. 12.0 %, p < 0.0001) and still diminished among patients receiving targeted therapies (2.6 %). PD was an independent prognostic factor of survival at multivariate analysis (35 % vs. 49 %, p = 0.0006). In the PD group, 3 independent prognostic factors were identified: carcinoembryonic antigen (CEA) ≥200 ng/mL (p = 0.003), >3 metastases (p = 0.028), and tumor diameter ≥50 mm (p = 0.002). A survival predictive model showed that patients without any risk factors had 5-year survival rates of 53.3 %; good survival results were still observed if metastases were >3 or ≥50 mm (29.9 and 19.1 %, respectively). On the contrary, survival was less than 10 % at 3 years in the presence of >1 prognostic factor or CEA of ≥200 ng/mL. CONCLUSIONS: PD is a negative
Published: 2012

31. NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis

Author: Montuschi, Paolo, Paris, D, Melck, D, Lucidi, V, Ciabattoni, G, Raia, V, Calabrese, C, Bush, A, Barnes, Pj, Motta, A., Montuschi, Paolo (ORCID:0000-0001-5589-1750), Montuschi, Paolo, Paris, D, Melck, D, Lucidi, V, Ciabattoni, G, Raia, V, Calabrese, C, Bush, A, Barnes, Pj, Motta, A., and Montuschi, Paolo (ORCID:0000-0001-5589-1750)
Abstract: Metabolomics could provide new insights into the pathophysiology of cystic fibrosis (CF) by identifying profiles of endogenous metabolites., BACKGROUND: Metabolomics could provide new insights into the pathophysiology of cystic fibrosis (CF) by identifying profiles of endogenous metabolites. OBJECTIVES: To investigate whether metabolomics of exhaled breath condensate could discriminate between patients with unstable CF, stable CF and healthy subjects, and whether selected metabolites were responsible for between-group differences. METHODS: Twenty-nine patients with stable CF, 24 with unstable CF and 31 healthy subjects (age 9-24 years) participated in a cross-sectional study. Metabolomics was performed with high-resolution nuclear magnetic resonance spectroscopy. Partial least squares-discriminant analysis was used as classifier. The results were validated in a second independent study. RESULTS: Intraclass correlation coefficients for between-day and technical repeatability were 0.93 and 0.96, respectively. Bland-Altman analysis showed good within-day repeatability. Correct classification rate of CF (n=53) vs. healthy subjects (n=31) was 96% (R2=0.84; Q2=0.79). Model validation with a testing sample set obtained from subjects not included in the primary analysis (23 CF and 25 healthy subjects) showed a sensitivity of 91% and a specificity of 96%. The classification rate of stable CF (n=29) vs. unstable CF patients (n=24) was 95% (R2=0.82; Q2=0.78). Model external validation in 14 patients with stable CF and 16 with unstable CF showed a sensitivity of 86% and a specificity of 94%. Ethanol, acetate, 2-propanol and acetone were most discriminant between patients with CF and healthy subjects, whereas acetate, ethanol, 2-propanol and methanol were the most important metabolites for discriminating between patients with stable and unstable CF. CONCLUSIONS: Nuclear magnetic resonance spectroscopy of exhaled breath condensate is reproducible, discriminates patients with CF from healthy subjects and patients with unstable CF from those with stable CF, and identifies the metabolites responsible for between-group di
Published: 2012

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Refine your results

31 results on '"Lucidi, V"'

1. Histopathological growth patterns of neuroendocrine tumor liver metastases

2. Dragon 1 Protocol Manuscript : Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

3. Dragon 1 Protocol Manuscript : Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

4. Long-term outcome of liver transplantation for unresectable liver metastases from Neuroendocrine neoplasms: a Belgian retrospective multi-centre study

5. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy.

6. Dragon 1 Protocol Manuscript : Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

7. Dragon 1 Protocol Manuscript : Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

8. Dragon 1 Protocol Manuscript : Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

9. Dragon 1 Protocol Manuscript:Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

10. A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation

11. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

12. Post cholecystectomy bile duct injury : early, intermediate or late repair with hepaticojejunostomy - an E-AHPBA multi-center study

13. Post cholecystectomy bile duct injury : early, intermediate or late repair with hepaticojejunostomy - an E-AHPBA multi-center study

14. Post cholecystectomy bile duct injury: early, intermediate or late repair with hepaticojejunostomy – an E-AHPBA multi-center study

15. Streptococcus pneumoniae oropharyngeal colonization in children and adolescents with cystic fibrosis

16. Streptococcus pneumoniae oropharyngeal colonization in children and adolescents with cystic fibrosis

17. Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis

18. Implementing carrier screening for cystic fibrosis outside the clinic: ethical analysis in the light of the personalist view

19. Long-term outcomes of patients with 10 or more colorectal liver metastases

20. Technical Aspects of Liver Transplantation - A Survey-Based Study within the Eurotransplant, Swisstransplant, Scandiatransplant and British Transplantation Society Networks

21. Technical Aspects of Liver Transplantation - A Survey-Based Study within the Eurotransplant, Swisstransplant, Scandiatransplant and British Transplantation Society Networks

22. Long-term outcomes of patients with 10 or more colorectal liver metastases

23. IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis

24. IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis

25. IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis

26. Nuclear magnetic resonance-based metabolomics discriminates primary ciliary dyskinesia from cystic fibrosis

27. NMR spectroscopy-based metabolomics of exhaled breath condensate in inflammatory respiratory diseases

28. Acoustic radiation force impulse (ARFI) imaging with Virtual Touch Tissue Quantification in liver disease associated with cystic fibrosis in children

29. Progression while receiving preoperative chemotherapy should snot be an absolute contraindication to liver resection for colorectal metastases

30. Progression while Receiving Preoperative Chemotherapy Should Not Be an Absolute Contraindication to Liver Resection for Colorectal Metastases

31. NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis

Catalog

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Publication Year Range

Publication Type

Database

Publisher

31 results on '"Lucidi, V"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources